New drugs in the therapy of neuroendocrine tumors

Journal of Endocrinological Investigation

Volumn 35, Issue 10, 2012, Pages 930-936

  Grozinsky Glasberg, S ^a   Gross, D J ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

mTOR inhibitors; NET; Neuroendocrine tumors; New drugs; Somatostatin analogues; Tyrosine kinases inhibitors

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DALOTUZUMAB; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MOTESANIB; NEW DRUG; OCTREOTIDE; PAZOPANIB; PEGINTERFERON ALPHA2B; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RIDAFOROLIMUS; S6 KINASE; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VATALANIB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CARCINOID; CARCINOID SYNDROME; CLASSIFICATION ALGORITHM; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULINOMA; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SHORT SURVEY; STOMATITIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS;

EID: 84871873415     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8651     Document Type: Short Survey

References (45)

1. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999, 10 (Suppl 2): S31-8. (Pubitemid 29288528)
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97: 934-59. (Pubitemid 36173145)
3. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451: 757-62. (Pubitemid 47497934)
4. Rindi G. The ENETS guidelines: the new TNM classification system. Tumori 2010, 96: 806-9.
5. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003, 10: 451-8. (Pubitemid 38094881)
6. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998, 32: 133-8. (Pubitemid 28126179)
7. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005, 8: 299-309. (Pubitemid 41443415)
8. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008, 15: 701-20.
9. Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005, 18: 1329-35. (Pubitemid 41348651)
10. Höpfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003, 89: 1766-75. (Pubitemid 37464152)
11. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004, 136: 1297-302. (Pubitemid 39647548)
12. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16: 525-37. (Pubitemid 40613318)
13. Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990, 39 (Suppl 2): 63-9. (Pubitemid 20286338)
14. Rinke A, Müller HH, Schade-Brittinger C, et al PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27: 4656-63.
15. Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol) 2012, 24: 282-93.
16. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24: 7455-64. (Pubitemid 41637985)
17. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18: 1926-45. (Pubitemid 39071573)
18. Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2008, 87: 168-81. (Pubitemid 351563811)
19. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26: 4311-8.
20. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28: 69-76.
21. Yao JC, Shah MH, Ito T, et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364: 514-23.
22. Pavel ME, Hainsworth JD, Baudin E, et al; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378: 2005-12.
23. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009, 360: 195-7.
24. Fiebrich HB, Siemerink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 2011, 16: 783-7.
25. Ferrer-García JC, Tolosa-Torréns M, Hernando-Meliá C, Arribas- Palomar L, Sánchez-Juan C. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract 2011, 17: e17-20.
26. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95: 1148-54. (Pubitemid 44660065)
27. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24: 401-6. (Pubitemid 46630459)
28. Gross DJ, Munter G, Bitan M, et al Israel Glivec in Solid Tumors Study Group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006, 13: 535-40. (Pubitemid 43886675)
29. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26: 1316-23.
30. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2007, 25 (Suppl): 4504 (abstract).
31. Castellano DE, Capdevila J, Salazar R, et al Spanish Neuroendocrine Tumor Group (GETNE). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol 2011, 29 (Suppl): 4113 (abstract).
32. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26: 3403-10.
33. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364: 501-13.
34. Phan AT, Yao JC, Fogelman DR, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010, 28 (Suppl): 4001 (abstract).
35. Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006, 84: 42-8. (Pubitemid 44973686)
36. Hobday TJ, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2006, 24 (Suppl): 4043 (abstract).
37. Reidy DL Hollywood E, Segal M, Saltz L. A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). J Clin Oncol 2010, 28 (Suppl): 4163 (abstract).
38. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver- directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011, 18: 127-37.
39. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22: 4762-71.
40. Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010, 102: 1106-12.
41. Delaunoit T, Ducreux M, Boige V, et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 2004, 40: 515-20. (Pubitemid 38220767)
42. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117: 268-75.
43. Eriksson B, Annibale B, Bajetta E, et al; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009, 90: 214-9.
44. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13: 2986-91. (Pubitemid 46849574)
45. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011, 117: 4617-22.